Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to $757,000.

  • Candel Therapeutics' Change in Accured Expenses rose 117.47% to $946,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$301,000, marking a year-over-year decrease of 123.79%. This contributed to the annual value of $757,000 for FY2024, which is 351.50% up from last year.
  • Per Candel Therapeutics' latest filing, its Change in Accured Expenses stood at $757,000 for FY2024, which was up 351.50% from -$301,000 recorded in FY2023.
  • In the past 5 years, Candel Therapeutics' Change in Accured Expenses ranged from a high of $1.5 million in FY2020 and a low of -$301,000 during FY2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $757,000 (2024), whereas its average is $573,667.
  • As far as peak fluctuations go, Candel Therapeutics' Change in Accured Expenses slumped by 123.79% in 2023, and later soared by 351.50% in 2024.
  • Over the past 5 years, Candel Therapeutics' Change in Accured Expenses (Yearly) stood at $1.5 million in 2020, then slumped by 80.36% to $297,000 in 2021, then soared by 325.93% to $1.3 million in 2022, then slumped by 123.79% to -$301,000 in 2023, then spiked by 351.50% to $757,000 in 2024.